Real Challenges. Real Solutions.
Precision therapies for genetically defined diseases
Who We Are

Cogent Biosciences is a biotechnology company developing real solutions to treat genetically driven diseases. With a focus on the design of rational precision therapies, we are leveraging validated biology to address the true underlying drivers of disease and provide real hope for patients.

Opportunity for Impact
Millions of people around the world are living with a genetically defined disease.
Mutations can create a ripple effect in the body to trigger illness – cancers, autoimmune conditions, and rare diseases.

For most of these diseases, despite the available therapies, there still exists a significant unmet need to extend survival and improve the quality of life for patients.

Advancing Best-in-Class
Precision Therapies
At Cogent, we start with the end in mind – with the goal of delivering meaningful therapies that improve human health. We focus on diseases where the cause is well understood and is directly linked to a genetic mutation, providing a path forward to develop novel precision therapies.
Explore
Discovering
New Solutions
We have built a world-class discovery organization in Boulder, Colorado, focused on pioneering best-in-class, small molecule therapeutics to improve upon existing drugs with clear limitations and safety concerns, with the goal of creating new breakthroughs for diseases where others have been unable to find adequate solutions.
Explore
Our People,
Our Promise
Cogent is driven by the patients we serve and committed to the opportunity to deliver novel precision therapies to patients with unmet medical needs. We are a Company of people who are passionate and dedicated to turning the promises of our therapies into reality in order to transform the lives of patients.
Explore
Latest News
March 14, 2023
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
Initiation of APEX Part 2 planned for mid-2023 Updated clinical data from Phase 3 PEAK lead-in in GIST patients expected 1H23 Initial clinical data from Phase 2 SUMMIT trial in NonAdvSM on-track for 2H23 Ended 2022 with $259.3 million in cash; sufficient to fund operations into 2025 WALTHAM, Mass.>
February 1, 2023
Cogent Biosciences Announces Participation at Upcoming Investor Conferences
WALTHAM, Mass. and BOULDER, Colo., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer, will
January 9, 2023
Cogent Biosciences Announces Planned 2023 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Cancer Therapeutics
Demonstrate significant progress toward leadership in Systemic Mastocytosis (SM), including mid-year Part 1 results from Phase 2 APEX trial in AdvSM patients and initial clinical data in 2H23 from Phase 2 SUMMIT trial in NonAdvSM patients Rapidly progress bezuclastinib in 2 nd -line
January 5, 2023
Cogent Biosciences Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass. and BOULDER, Colo., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer will present
Scroll to Top